Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14434936 | 0.85 | BRAF (0.43) | ALDH1A1MAPK1HTTNPC1MAPT | |
| SCHEMBL10120031 | 0.82 | MAPT (0.54) | SMN1; SMN2ALDH1A1HTTNPC1MAPT | |
| SCHEMBL11441588 | 0.82 | CYP1A2 (0.47) | SMN1; SMN2ALDH1A1MAPK1HTTNPC1 | |
| SCHEMBL28620570 | 0.82 | MAPK1 (0.47) | SMN1; SMN2ALDH1A1MAPK1NPC1MAPT | |
| SCHEMBL200831 | 0.80 | MAPK1 (0.63) | SMN1; SMN2ALDH1A1MAPK1NPC1MAPT | |
| SCHEMBL10712366 | 0.79 | CYP1A2 (0.53) | SMN1; SMN2ALDH1A1MAPK1NPC1MAPT | |
| SCHEMBL11436903 | 0.79 | MAPK1 (0.44) | SMN1; SMN2ALDH1A1MAPK1NPC1MAPT | |
| SCHEMBL10707004 | 0.79 | POLB (0.60) | SMN1; SMN2ALDH1A1MAPK1HTTNPC1 | |
| SCHEMBL30490040 | 0.79 | MAPT (0.47) | SMN1; SMN2ALDH1A1MAPK1HTTNPC1 | |
| SCHEMBL18216839 | 0.78 | GRN (0.56) | SMN1; SMN2ALDH1A1KDM4EMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143287-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143287-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8093251-B2 | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-8053453-B2 | Pyrazolone compounds and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-20100323965-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100323965-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-7786159-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786159-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070583-A2 | THROMBOPOIETIN MIMETICS | STATEGICS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| US-20060069140-A1 | Pyrazolone compounds and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-03-30 | — | — | US | disclosed |
| EP-1549618-A1 | PYRAZOLONE COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004033433-A1 | PYRAZOLONE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139621-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | SMN1; SMN2 1872/4885ALDH1A1 2613/4885MAPK1 1750/4885 |
| US-20100323965-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | SMN1; SMN2 1872/4885ALDH1A1 2613/4885MAPK1 1750/4885 |
| US-20060069140-A1 | Pyrazolone compounds and thrombopoietin receptor activator | MPL, PDGFRA, THPO | SMN1; SMN2 2350/4885ALDH1A1 1338/4885MAPK1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.